US/UK/Canada

Share

Links

Quotes

In every aspect, this was an amazing journey, Getting such broad feedback from end users was invaluable, both for us and our distributor.
Magdalena Tharaldsen, Director International Business Development.
I very much look forward to being involved in the management and development of Calmark, a company with thrilling times ahead
Madeleine Skoglund, CFO
Calmark's products are suitable for all markets worldwide. However, we choose to prioritize the markets where we already have good collaborations and see that launch and sales can take place in the near future.
Anna Söderlund, CEO Calmark
Getting such positive feedback directly from end users in hospitals has been priceless, everyone truly appreciates the value of the product.
Magdalena Tharaldsen, Calmark’s Director International Business Development
The products will be delivered to end customers in the Northern regions, according to the roll-out plan.
Magdalena Tharaldsen, Director International Business Development at Calmark
We have worked really hard to develop a product that is feasible worldwide. Both in highly developed healthcare systems and in low-income countries. The fact that we are now getting noticed and receive the quality seal "NEST360 Qualified" is a big and important milestone for us and a proof that we have succeeded!
Anna Söderlund, CEO
It is with deep satisfaction that we announce the CE conformity marking of our product COVID19-LDH
Anna Söderlund, CEO
It is truly inspiring and heartening to join the Calmark team and be able to make use of my experience in a new context
Magdalena Tharaldsen, Director of International Business Development
We are very pleased with the collaboration with Triolab and it feels great that we can now reach more markets together.
Marianne Alksnis, International Sales Director of Calmark
It is with heartfelt satisfaction that we announce the CE conformity marking of our first product
Anna Söderlund, CEO
I am very proud to have been proposed to chair the Board of Directors of Calmark Sweden AB in this pivotal stage of the Company's development. I see tremendous potential in the company and its products; POC diagnostics is a rapidly growing area and Calmark's offering is strong. It is also good to know that Mathias will remain on the board so that he can continue to share his knowledge.
Kjersti Berg Marthinsen
We have held meetings with more than 50 actors and been given unique opportunities to demonstrate our platform and discuss partnerships around sales.
Marianne Alksnis, International Sales Director
Pick a time period -
Tags ( Active)

Calmark extends the shelf life of the test cassettes to 2 years.

Calmark Sweden AB (publ) announces today that they have extended the shelf life of the test cassettes to 24 months. The decision has been taken after internally conducted studies. The batch that has now been produced can be used until January 2026, which is deemed to meet the market's needs.Calmark has produced a new batch of test cassettes using its fully automated production line to meet upcoming deliveries. As a medical technology manufacturer, it has great demands on itself to prove the durability of its products. This can be difficult with new products and real-time studies are often

Calmark relaunches Neo-Bilirubin in Finland

Calmark Sweden AB announces today that they have started a relaunch of the product Neo-Bilirubin in Finland together with its distributor Triolab Oy. Triolab has placed an order of less economic value which has been delivered. The product will be exhibited at Lab Quality Days, an exhibition held in Helsinki during this week.Calmark Sweden Ab already has a distributor agreement with Triolab Oy in Finland. The collaboration has now intensified after Calmark's product Neo-Bilirubin can also be used for capillary sampling. The product will be exhibited at a fair in Helsinki during the week. "

Calmark receives recurring orders from Greece

Calmark Sweden AB announced today that they have received a repeat order from the distributor Prime Bioscience in Greece. Today's order has a smaller financial value, but is important from a launch perspective.Use of capillary sampling, as press release 240130, is an important factor for the Greek market. The interest in Calmark's Neo-Bilirubin product is big and now being able to also use capillary samples facilitates the launch. "Our collaboration with Prime Bioscience in Greece is very good. We are happy that there are recurring orders from them and that the launch is progressing,"

Calmark's product Neo-Bilirubin can now be used for capillary sampling

Calmark Sweden AB announces today that their instruments can now also be used for blood from capillary sampling. The conclusion is based on the study carried out in Greece in 2023. In Sweden, venous sampling of newborn children is the most used, but in several countries in the world capillary sampling of newborn children is a common method. This change is an important step to reach more markets.Calmark's product Neo-Bilirubin has previously only been recommended for venous samples, i.e. sticking a vessel on the hand or arm. In Sweden, it is the most common method of taking blood samples

Calmark receives patent in India

Calmark Sweden AB (publ) announces today that Intellectual Property of India has approved the company's patent application regarding Calmark's test cassette and the construction of volume control, so-called 'Exact fill'. The patent is valid until 2038.The patent with the title "Detection of a biomarker in a flowable substance" and patent number 496567 covers Calmark's test cassette. Including the new patent, Calmark owns 22 patents and 11 design protections for both the instrument and the disposable test in important markets. "Today's announcement is gratifying," says Anna Söderlund,

Calmark's instruments gets connected to journal systems

Calmark Sweden AB (publ) collaborates with Zafena AB to connect instruments to the hospital's record system. The update is expected to be launched in the spring of 2024.Calmark collaborates with Zafena to be able to offer connection to the hospitals' IT systems. Zafenas offers the solution Zafena POC-Workstation, which is a flexible workstation, gateway and access point. The workstation stores response history and can print the result. The workstation can also communicate bidirectionally with medical record and lab data systems, which means that a workstation can, for example, receive a lab

Calmark obtains a patent in Vietnam

Calmark Sweden AB (publ) announces today that the Vietnamese Patent Office has approved the company's patent application regarding "POC test system for biomarker". The patent is valid until January 2038.The patent with the title "POC test system for biomarker" and patent number 38081 covers the entire Calmark system with both test cassette and reader. Including the new patent, Calmark owns 21 patents and 11 design protections regarding both the instrument and the disposable test in important markets. "Today's announcement is gratifying," says Anna Söderlund, CEO of Calmark. "For

Calmark signs distributor agreement with Techno Orbits in Saudi Arabia

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with the company Techno Orbits in Saudi Arabia regarding Calmark's bilirubin test for newborns.Techno Orbits was founded in 2007 and is a well-established and successful company with a large market share and extensive experience in the medical technology industry. Company is headquartered in Riyadh and several branches in Saudi Arabia and Amman. The company has approximately 150 employees and has good contacts with the Ministry of Health. Techno Orbits is the market leader in PNA testing and has

Calmark Sweden AB announces the last day of trading in BTU and the first day of trading in warrants of series TO 4 B

Calmark Sweden AB:s ("Calmark" or the "Company") preferential issue of units, with a subscription period that ended on November 10, 2023, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is December 4, 2023, and the stop day is December 6, 2023. The first day of trading in warrants of series TO 4 B is December 8, 2023.In October/November 2023, Calmark carried out a rights issue which provided the Company with approximately SEK 8.56 million before issue costs. The rights issue has now

Calmark Sweden AB publishes outcome of rights issue

The subscription period in Calmark Sweden AB ("Calmark" or the "Company") rights issue of units ended on the 10 November 2023. The rights issue was subscribed to a total of approximately 40.6 percent, including pre-subscription commitments, meaning that guarantee commitments of a total of approximately 19.4 percent were activated to achieve a total subscription rate of 60 percent. Calmark will thus be provided proceeds of approximately SEK 8.56 million before deduction of transaction related costs.Anna Söderlund, CEO of Calmark, comments ”With the capital from the issue we can focus on

Calmark Sweden AB participates in Medica in Germany

Calmark Sweden AB will participate in the medical technology fair Medica between November 13 and 17. Medica is one of the world's largest B2B fairs for medical technology companies with 4,500 exhibitors and over 80,000 visitors. The company will meet existing and potential distributors.Medica is an annual B2B fair in Düsseldorf that gathers approx. 80,000 participants from more than 60 countries. Calmark will attend to meet its distributors and meet new potential distributors and partners. "Medica is an important event during the autumn, an opportunity to meet most of our partners in one

Calmark receives Notice of Allowance regarding patent in USA

Calmark Sweden AB (publ) announces today that the US Patent Office ("USPTO") has issued a so-called Notice of Allowance regarding Calmark's test cassette and the construction of volume control, so-called 'Exact fill'The patent with the title "Exact fill" and application number 17/254609 covers the design of the test cassette for volume control of the blood sample amount. The patent provides protection until 2040. The Notice of Allowance means that the USPTO will approve the company's patent application. Including the new patent, Calmark owns 20 patents and 11 design protections regarding

Calmark ships instruments to India for a method comparison study

Calmark Sweden AB announces today that they are sending 2 units with associated bilirubin test cassettes to the distributor r2 Diagsnostics in India. The distributor plans to use the products for a method comparison.Calmark, together with r2 Diagnostics, has been working for a long time for a registration of Calmark Neo – Bilirubin on the Indian market. r2 Diagnostics plans to carry out a method comparison at state-accredited laboratories in the country. The result of the method comparison will be submitted to the registration authority in India as a supplement to other submitted material.

Calmark presentation at investors meeting at Financial Stockholm

Calmark Sweden AB's ("Calmark" or "the Company") Chairman of the board Mathias Karlsson has presented at Financial Stockholm. The presentation is available via link below. The subscription period in the Company’s rights issue of units runs until the 10[th] of November 2023.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE

Calmark Sweden AB: CEO-interview with Finwire

Calmark Sweden AB's ("Calmark" or "the Company") CEO Anna Söderlund has been interviewed by Finwire TV. The video interview has been published and is available via link below. The subscription period in the Company’s rights issue of units runs until the 10[th] of November 2023.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE

The subscription period in Calmark's rights issue of units begins today

Today, October 27, 2023, the subscription period in Calmark Sweden AB's ("Calmark" or "the Company") rights issue of units (the "Rights Issue"), with preferential rights for the Company's existing shareholders, begins. The subscription period ends on November 10, 2023. The issue volume initially amounts to a maximum of approximately SEK 14.3 million before transaction related costs. Upon full subscription of the Rights Issue and full use of TO 4 B, the Company will receive an additional approximately SEK 7.1 million before transaction related costs. The rights issue is secured in advance in

Calmark publishes memorandum for rights issue

The extraordinary general meeting of Calmark Sweden AB ("Calmark" or the "Company") decided on October 18, 2023, in accordance with the board's proposal, to carry out a rights issue of units (the "Rights Issue"). For the Rights Issue, Calmark has drawn up a memorandum containing information about the Company and the Rights Issue, which is now available via the Company's (www.calmark.se), the financial advisor Sedermera Corporate Finance AB’s (www.sedermera.se) and the issuing agent Nordic Issuing AB’s (www.nordic-issuing.se) respective websites. The subscription period begins on 27 October

Calmark supplies products to Global Health Labs

Calmark Sweden AB announce today that they deliver a platform with associated test cassettes to Global Health Labs in Seattle, WA, USA. Global Health Labs is a non-profit company fully funded by Gates Ventures (Bill Gates' private investment fund), and partners with the Bill & Melinda Gates Foundation and other cross-sector leaders to develop health technology solutions. Right now they are investigating all products in the world that are NEST360 certified.Global Health Labs is primarily an organization that develops and improves products for low-income countries. They have no manufacturing

The Board of Directors of Calmark proposes for the extraordinary general meeting to decide on a rights issue in order to identify partners and accelerate sales activities

The Board of Directors of Calmark Sweden AB ("Calmark" or the "Company") has today, on September 15, 2023, decided to propose for the extraordinary general meeting in the Company, planned to be held on October 18, 2023, to decide to carry out an issue of units (the "Rights Issue") consisting of shares and free warrants of series TO 4 B ("TO 4 B"), with preferential rights for the Company's existing shareholders. The issue volume for the issued shares in the Rights Issue amounts to a maximum of approximately SEK 14.3 million before transaction costs. In the event of full subscription of the

Calmark receives order from Turkey regarding Neo-products.

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Turkey, Savas Medical covering the Calmark Neo platform. The economic value of today's order is of minor importance, but it is important from a launch perspective‘The registration of Neo-Bilirubin in Turkey was completed last week. The fact that our distributor places an order immediately is positive and shows that they, just like us, have been waiting to get started with the launch.’  says Magdalena Tharaldsen, Director International Business Development for Calmark.

Calmark's Neo product for bilirubin is registered in Turkey

Calmark Sweden AB (publ) announced today that the company’s point-of-care test for bilirubin has been registered in Turkey. The registration covers both the test cassette Neo-Bilirubin and the instrument, POC-Analyzer Neo. Today's announcement means sales of Calmark Neo-Bilirubin can start in Turkey.Calmark cooperates with the company Savas Medikal regarding launch, registration and sales on the Turkish market. The company has now listed Calmark's product in the country's "Product Tracking System", which means that sales can start. Savas Medikal and Calmark have a detailed plan in place for

Calmark receives follow-up order from Italy

Calmark announced today that the company received another follow-up order from Italy regarding the Neo-Bilirubin test cassettes.Calmark receives another recurring order from Italy for test cassettes, which shows that the clinics in Italy that previously purchased Calmark POC instruments and test cassettes are still using the products. Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

Calmark receives demo order from Puerto Rico

As part of Calmark Sweden AB's collaboration with VIA Global Health, the company announces today that the first demo order has been received for Puerto Rico and will now be delivered.VIA Global Health focuses primarily on low- and middle-income countries and aims to enable the distribution of important medical technology products to those parts of the world where the need is great, but where regular launches are often not a priority for most manufacturers. Today's order covers one instrument and a number of testcassettes that will not be used in healthcare for diagnostic purposes.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media